<DOC>
	<DOCNO>NCT02409459</DOCNO>
	<brief_summary>This study investigate efficacy safety IV iron Injectafer treatment iron deficient patient fibromyalgia . Eligible subject randomize 1:1 ratio receive Injectafer Placebo day 0 5 . All treated subject follow efficacy safety 42 day .</brief_summary>
	<brief_title>A Blinded , Randomized , Placebo-Controlled Study Investigate Efficacy Safety Injectafer Treatment Iron Deficient Patients With Fibromyalgia</brief_title>
	<detailed_description>This blind , randomize , placebo-controlled study . All subject meet inclusion requirement exclusion criterion enter 14 day screen phase . Eligible subject randomize 1:1 ratio receive Injectafer Placebo day 0 5 . All treated subject follow efficacy safety 42 day . Subjects visit clinic day 0 5 treatment , day 14 , 28 , 42 . The subject 's participation study approximately 42 day day 0 .</detailed_description>
	<mesh_term>Fibromyalgia</mesh_term>
	<mesh_term>Myofascial Pain Syndromes</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Male female subject 's ≥ 18 year age , able give inform consent study . Fibromyalgia diagnosis base The 2011 modification American College Rheumatology ( ACR ) 's 2010 preliminary criterion diagnose fibromyalgia ( 2011ModCr ) A baseline score ≥ 60 FIQR Subject 's current medication treat fibromyalgia , include pain medicine , antidepressant , sleep medication must stable dose least 30 day . Subject 's current narcotic medication must stable dose least 30 day prior randomization Subjects risk pregnancy must negative pregnancy test baseline practice acceptable form birth control : hysterectomy tubal ligation , otherwise incapable pregnancy , practice follow method contraception least one month prior study entry : hormonal contraceptive , spermicide barrier , intrauterine device , partner sterility . Parenteral iron use within 4 week prior screen . History &gt; 10 blood transfusion past 2 year . Anticipated need blood transfusion study . Known hypersensitivity reaction component Injectafer® ( Ferric Carboxymaltose ) . Current acute chronic infection viral upper respiratory tract infection Malignancy ( basal squamous cell skin cancer subject cancer free ≥ 5 year ) . Active inflammatory arthritis ( e.g . rheumatoid arthritis , SLE ) . Pregnant lactating woman . Severe peripheral vascular disease significant skin change . Seizure disorder currently treat medication . Baseline ferritin ≥ 50 ng/mL . Baseline TSAT ≥ 20 % . History hemochromatosis hemosiderosis iron storage disorder . Known positive hepatitis evidence active disease . Hemoglobin great upper limit normal . Calcium phosphorous outside normal range . Known positive hepatitis B antigen ( HBsAg ) hepatitis C viral antibody ( HCV ) evidence active hepatitis ( i.e. , AST/ALT great upper limit normal ) . Known positive HIV1/HIV2 antibody ( antiHIV ) Received investigational drug within 30 day randomization . Chronic alcohol drug abuse within past 6 month . Any preexist laboratory abnormality , medical condition disease view investigator participation study may put subject risk . Subject unable comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>